Chesterford occupier, Axol Bioscience, specialists in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, today announced Paul Andrews as their Scientific Advisory Board Member.
Dr Andrews is an expert in the industrial application of stem cells in phenotypic screening, having previously used this platform to identify agents that steer cell fate. He will aid Axol in ensuring its commercially available human primary and induced pluripotent stem cell (iPSC)-derived cells continue to enable the development of pathophysiologically-relevant systems for industrial and academic research.
Paul Andrews, BSc PhD FRSB is Director of Operations at the National Phenotypic Screening Centre (NPSC), a new open collaborative venture based at the Universities of Dundee, Oxford and Edinburgh. Dr Andrews also sits on the editorial board for Current Research in Drug Discovery and is a Fellow of the Royal Society of Biology. He has been a Trustee of the British Society of Cell Biology, Advisory Board Member of the Scottish Stem Cell Network and was team leader in Cellartis/Cellectis Stem Cells. Prior to this he was team leader for the Stem Cell Technology Programme in the Drug Discovery Unit at The University of Dundee and has over 20 years of postdoctoral research experience in cell and molecular biology.